Loading clinical trials...
Loading clinical trials...
The purpose of this study is to assess the effectiveness of RaPID/BSI by testing its performance compared to blood cultures collected prospectively from consented subjects.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
HelixBind, Inc.
NCT04886284 · Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia, and more
NCT07134751 · Febrile Illness Acute, Meningitis, Bacterial, and more
NCT06650501 · Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, and more
NCT05421858 · Candidemia, Candidiasis, Invasive
NCT06966284 · Bacteremia Caused by Gram-Negative Bacteria, Bacterial Pneumonia
HelixBind Inc.
Marlborough, Massachusetts
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions